About Us

Indication Bioscience is a biopharmaceutical company advancing innovative therapies in cardiovascular and metabolic disease.

Our lead program, Atorvo+™, is a fixed-dose combination therapy designed to enhance the clinical utility of statins by addressing well-recognized challenges of tolerability and long-term adherence.

The Phase I pharmacokinetic (PK) study of Atorvo+™ has been successfully completed, following approval by the Alfred Health Human Research Ethics Committee (HREC) and execution at Nucleus Network under the oversight of Novotech. Completion of this study establishes a strong clinical foundation and supports continued development toward FDA engagement and Phase II planning.

Supported by a robust intellectual property portfolio covering statin-combination technologies and guided by a leadership team with deep experience in cardiovascular drug development—including key roles in the Lipitor® launch and Phase III programs for bempedoic acid—Indication Bioscience is building a scalable platform aimed at improving outcomes for patients who rely on statin therapy.

Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering pharmaceuticals, and are among the most widely prescribed class of drugs. The Statin+ concept represents a groundbreaking approach to cholesterol management by combining proven statin therapies with complementary active ingredients to address the widespread challenge of statin intolerance. By targeting the muscle-related side effects that lead to poor adherence, Statin+ therapies aim to enhance tolerability and improve patient outcomes. This innovative fixed-dose combination strategy leverages existing FDA-approved therapies through accelerated development pathways, offering a de-risked and cost-effective solution to optimize treatment adherence in millions of patients globally.